10 Multiple Myeloma Clinical Trials in Louisville, KY (2026)

Q: How do I join a clinical trial in Louisville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Louisville research site will contact you.

Recruiting Multiple Myeloma Studies in Louisville

NCT04634552Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....

Louisville, KYPHASE2510 participantsJanssen Research & Development, LLC

View Study Details

NCT05730036Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had adv...

Louisville, KYPHASE3410 participantsRegeneron Pharmaceuticals

View Study Details

NCT03761108Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs ...

Louisville, KYPHASE1387 participantsRegeneron Pharmaceuticals

View Study Details

NCT06722235Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...

Louisville, KYPHASE3171 participantsTakeda

View Study Details

NCT06948318Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making i...

Louisville, KYPHASE3150 participantsTakeda

View Study Details

NCT05828511Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high d...

Louisville, KYPHASE1149 participantsRegeneron Pharmaceuticals

View Study Details

NCT04879043Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma....

Louisville, KYPHASE178 participantsHeidelberg Pharma AG

View Study Details

NCT07280013Recruiting

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of...

Louisville, KYPHASE160 participantsC4 Therapeutics, Inc.

View Study Details

NCT03953768Recruiting

VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems

Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for ...

Louisville, KYNA30 participantsUniversity of Louisville

View Study Details

NCT04929236Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

Louisville, KYPHASE330 participantsOctapharma

View Study Details

About Multiple Myeloma Clinical Trials in Louisville

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 10 multiple myeloma clinical trials recruiting participants in Louisville, KY. These studies are seeking a combined 1,975 participants. Research is being sponsored by Janssen Research & Development, LLC, Regeneron Pharmaceuticals, Takeda and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Louisville — FAQ

Are there multiple myeloma clinical trials in Louisville?

Yes, there are 10 multiple myeloma clinical trials currently recruiting in Louisville, KY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Louisville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Louisville research site will contact you about next steps.

Are clinical trials in Louisville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Louisville studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 10 active trials in Louisville are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 18, 2026 from ClinicalTrials.gov